The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Genetic modulation of drug response can cause life-threatening adverse drug reactions, increase susceptibility to drug interactions and alter therapeutic effectiveness. Pharmacogenomics has the potential to immediately impact the care of patients and is a hallmark of genomic medicine worldwide. Ideally, pharmacogenomics-guided drug selection will produce optimal effects for specific indications, reduce delays in care to effective therapies, improve patient safety and reduce health care costs. Over the past decade, a large number of pharmacogenomic variants with demonstrated clinical utility have been identified and corresponding international guidelines for clinical implementation have been developed and published by the Clinical Pharmacogenetics Implementation Consortium (CPIC), Canadian Pharmacogenomics Network for Drug Safety (CPNDS) and Royal Dutch Association for the Advancement of Pharmacy Dutch Pharmacogenetics Working Group (DPWG). There is now general agreement that pharmacogenomics represents an area within genomic science that could have a significant positive impact on clinical medicine and, ultimately, affect every patient. Via The International Journal of Epidemiology.